Table 3.

Efficacy Data for Mobocertinib and Amivantamab Treatment of EGFRex20ins Mutation NSCLC Patients Previously Treated with Platinum-Based Chemotherapy

	Mobocertinib (PPP) (n = 114)	CHRYSALIS (n =81)
Median Age – years (range)	60 (27–84)	62 (42–84)
Female – no.(%)	75 (66)	48 (59)
Stable brain lesions – no.(%)	40 (35)	18 (22)
Overall Response Rate (ORR) - % (95% CI)	28 (20–37)	40 (29–51)
Median Duration of Response (mDOR) – months (95% CI)	17.5 (7.4–20.3)	11.1 (6.9-NR)
Median Progression-Free Survival (mPFS) – months (95% CI)	7.3 (5.5–9.2)	8.3 (6.5–10.9)
Median Overall Survival (mOS) – months (95% CI)	24.0 (14.6–28.8)	22.8 (14.6-NR)